Ned Pagliarulo

Lead Editor at BioPharma Dive

Lead editor @BioPharmaDive

Featured in: Favicon

biopharmadive.com Favicon

utilitydive.com Favicon

healthcaredive.com Favicon

fooddive.com Favicon

supplychaindive.com Favicon

ciodive.com Favicon

k12dive.com Favicon

medtechdive.com Favicon

cfodive.com Favicon

industrydive.com + 8 more

Articles

FDA meeting gives window into gene therapy field’s angst

3 weeks ago | biopharmadive.com | Ned Pagliarulo

Anyone looking for evidence of genetic medicine’s enormous promise need only read of KJ Muldoon. The 10-month-old infant headed home from a Philadelphia hospital this week, dressed in a celebratory cap and gown, after his life-threatening disease was successfully treated with a bespoke CRISPR therapy. While baby KJ is not cured, the treatment has stabilized his disease, a rare liver condition known as CSP1 deficiency, to such extent he’s able to resume eating a normal diet.
FDA meeting gives window into gene therapy field’s angst

3 weeks ago | yahoo.com | Ned Pagliarulo

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Anyone looking for evidence of genetic medicine’s enormous promise need only read of KJ Muldoon. The 10-month-old infant headed home from a Philadelphia hospital this week, dressed in a celebratory cap and gown, after his life-threatening disease was successfully treated with a bespoke CRISPR therapy.
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO

3 weeks ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

New drugs, however heralded, take time to embed into clinical care. Enhertu, the powerful antibody-drug conjugate from Daiichi Sankyo and AstraZeneca, was first approved in the U.S. in 2019, before the world had even heard of a novel coronavirus.
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.

3 weeks ago | biopharmadive.com | Ned Pagliarulo

CHICAGO — Hiroyuki Okuzawa holds an enviable position. The veteran Daiichi Sankyo executive took over as the Japanese drugmaker’s new CEO two months ago and inherited a company whose cancer medicines have, over the past half-decade, won it three of the pharmaceutical industry’s largest licensing deals.
Bispecific competition, debating oral SERDs and a bold GLP-1 prediction

3 weeks ago | biopharmadive.com | Delilah Alvarado |Jonathan Gardner |Ned Pagliarulo

CHICAGO — The American Society of Clinical Oncology’s annual meeting is a forum for data. On Monday, it was also the backdrop to oncology’s latest deal, when Bristol Myers Squibb and BioNTech announced a multibillion-dollar alliance around a newly in-vogue drug. BioNTech’s drug is a bispecific antibody that simultaneously targets the proteins PD-L1 and VEGF.
AstraZeneca drug could help keep a common breast cancer at bay

3 weeks ago | medtechdive.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. CHICAGO — Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1.
Enhertu potential broadens as new data point to frontline breast cancer role

3 weeks ago | biopharmadive.com | Ned Pagliarulo

CHICAGO — Enhertu, the antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, year by year proves more indispensable in the treatment of metastatic breast cancer. Already enmeshed in clinical practice as a go-to choice for tumors that have come back once, Enhertu could soon have a role to play in initial treatment as well.
Bristol Myers allies with BioNTech on bispecific cancer drug

3 weeks ago | biopharmadive.com | Ned Pagliarulo

Bristol Myers Squibb is making sure it won’t miss out on a new type of cancer immunotherapy that’s drawn immense industry interest, announcing Monday an alliance with BioNTech on a bispecific antibody the German biotechnology company is developing. Dubbed BNT327, the antibody drug takes aim at two proteins — PD-L1 and VEGF — that are among the most important cancer drug targets of the past two decades.
A funding flashpoint, Pfizer’s $1B poster and AstraZeneca advertising

3 weeks ago | biopharmadive.com | Ned Pagliarulo |Jonathan Gardner

Funding cancer research isn't usually a political flashpoint. But as the Trump administration signals its desire to drastically cut the budget of the National Cancer Institute, the American Society of Clinical Oncology is finding itself forced to defend what is usually a bipartisan policy. "If implemented, these cuts would be devastating to the pace and progress of cancer research in America," ASCO CEO Clifford Hudis said in a Friday statement.
AstraZeneca drug could help keep a common breast cancer at bay

3 weeks ago | biopharmadive.com | Ned Pagliarulo

Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1. Mutations there can drive cancer growth even as physicians’ first choice of therapy chokes off the resources that tumors had relied on to survive. Afterwards, the prognosis for patients gets worse.